Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 415

1.

REBOUND "Trained to live again": The practice of great Olympic coaches improves and enhances the quality of life of cancer patients in remission after hematopoietic stem cell allogeneic transplantation.

Blaise D, Calvin S, Cuvelier S, Ben Soussan P, Villaron C, Dantin P, Viens P.

Bone Marrow Transplant. 2020 Mar 2. doi: 10.1038/s41409-020-0845-1. [Epub ahead of print] Review. No abstract available.

PMID:
32123291
2.

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.

Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S.

Mol Oncol. 2020 Mar;14(3):504-519. doi: 10.1002/1878-0261.12621. Epub 2020 Feb 5.

3.

[E-health and "Cancer outside the hospital walls", Big Data and artificial intelligence].

Bertucci F, Le Corroller-Soriano AG, Monneur A, Fluzin S, Viens P, Maraninchi D, Goncalves A.

Bull Cancer. 2020 Jan;107(1):102-112. doi: 10.1016/j.bulcan.2019.07.006. Epub 2019 Sep 19. Review. French.

PMID:
31543271
4.

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.

de Nonneville A, Finetti P, Adelaide J, Lambaudie É, Viens P, Gonçalves A, Birnbaum D, Mamessier E, Bertucci F.

Cancers (Basel). 2019 Aug 13;11(8). pii: E1158. doi: 10.3390/cancers11081158.

5.

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review.

Planes-Laine G, Rochigneux P, Bertucci F, Chrétien AS, Viens P, Sabatier R, Gonçalves A.

Cancers (Basel). 2019 Jul 22;11(7). pii: E1033. doi: 10.3390/cancers11071033. Review.

6.

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.

Tyran M, Carbuccia N, Garnier S, Guille A, Adelaïde J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F.

Cancers (Basel). 2019 May 13;11(5). pii: E665. doi: 10.3390/cancers11050665.

7.

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer.

Sabatier R, Charafe-Jauffret E, Pierga JY, Curé H, Lambaudie E, Genre D, Houvenaeghel G, Viens P, Ginestier C, Bertucci F, Sfumato P, Extra JM, Gonçalves A.

J Clin Med. 2019 May 6;8(5). pii: E612. doi: 10.3390/jcm8050612.

8.

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.

Bertucci F, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola FM, Viens P, Mamessier E, Ceccarelli M, Birnbaum D, Bedognetti D.

Br J Cancer. 2018 Nov;119(11):1383-1391. doi: 10.1038/s41416-018-0309-1. Epub 2018 Oct 24.

9.

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer.

Guerin M, Gonçalves A, Toiron Y, Baudelet E, Pophillat M, Granjeaud S, Fourquet P, Jacot W, Tarpin C, Sabatier R, Agavnian E, Finetti P, Adelaide J, Birnbaum D, Ginestier C, Charafe-Jauffret E, Viens P, Bertucci F, Borg JP, Camoin L.

Oncotarget. 2018 Sep 18;9(73):33762-33777. doi: 10.18632/oncotarget.26031. eCollection 2018 Sep 18.

10.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
11.

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.

Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal M, Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A.

Cancer Res Treat. 2018 Oct;50(4):1226-1237. doi: 10.4143/crt.2017.446. Epub 2017 Dec 28.

12.

Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.

de Nonneville A, Sabatier R, Gonçalves A, Extra JM, Tarpin C, Launay S, Tassy L, Viens P, Rousseau F.

J Geriatr Oncol. 2018 May;9(3):281-283. doi: 10.1016/j.jgo.2017.11.003. Epub 2017 Nov 22. No abstract available.

PMID:
29174186
13.

[Sport coaching for psychological and social recovery after hematological cancer: An innovative perspective].

Calvin S, Blaise D, Ben Soussan P, Cuvelier S, Cicut N, Caymaris L, Arnault Y, Onesta C, Dantin P, Viens P.

Bull Cancer. 2017 Oct;104(10):823-830. doi: 10.1016/j.bulcan.2017.08.006. Epub 2017 Oct 12. French.

PMID:
29031507
14.

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.

Monneur A, Goncalves A, Gilabert M, Finetti P, Tarpin C, Zemmour C, Extra JM, Tallet A, Lambaudie E, Jacquemier J, Houvenaeghel G, Boher JM, Viens P, Bertucci F.

Oncotarget. 2017 Jul 31;8(39):66019-66032. doi: 10.18632/oncotarget.19732. eCollection 2017 Sep 12.

15.

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.

Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, Provansal M, Camerlo J, Sabatier R, Bertucci F, Charafe-Jauffret E, Hervieu A, Extra JM, Viens P, Lokiec F, Boher JM, Gonçalves A.

Eur J Cancer. 2017 Nov;86:28-36. doi: 10.1016/j.ejca.2017.08.025. Epub 2017 Sep 23.

PMID:
28950146
16.

Diversity of family GH46 chitosanases in Kitasatospora setae KM-6054.

Zitouni M, Viens P, Ghinet MG, Brzezinski R.

Appl Microbiol Biotechnol. 2017 Nov;101(21):7877-7888. doi: 10.1007/s00253-017-8517-9. Epub 2017 Sep 18.

17.

The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?

Gonçalves A, Monneur A, Viens P, Bertucci F.

Expert Rev Anticancer Ther. 2017 Jul;17(7):593-606. doi: 10.1080/14737140.2017.1330655. Epub 2017 May 25. Review.

PMID:
28506194
18.

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

Kerbrat P, Desmoulins I, Roca L, Levy C, Lortholary A, Marre A, Delva R, Rios M, Viens P, Brain É, Serin D, Edel M, Debled M, Campone M, Mourret-Reynier MA, Bachelot T, Foucher-Goudier MJ, Asselain B, Lemonnier J, Martin AL, Roché H.

Eur J Cancer. 2017 Jul;79:166-175. doi: 10.1016/j.ejca.2017.03.004. Epub 2017 May 11.

PMID:
28501763
19.

A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study.

Chanez B, Bertucci F, Gilabert M, Madroszyk A, Rousseau F, Perrot D, Viens P, Raoul JL.

Support Care Cancer. 2017 Sep;25(9):2715-2722. doi: 10.1007/s00520-017-3680-1. Epub 2017 Mar 28.

PMID:
28353038
20.

[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Bull Cancer. 2017 Apr;104(4):332-343. doi: 10.1016/j.bulcan.2016.12.007. Epub 2017 Feb 16. French.

PMID:
28214007
21.

Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France.

Protiére C, Baker R, Genre D, Goncalves A, Viens P.

Med Decis Making. 2017 Jul;37(5):555-566. doi: 10.1177/0272989X17691953. Epub 2017 Feb 15.

PMID:
28199180
22.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P.

Ann Oncol. 2017 Jan 1;28(1):103-109. doi: 10.1093/annonc/mdw535.

23.

Bevacizumab in HER2-negative inflammatory breast cancer.

Bertucci F, Goncalves A, Viens P.

Oncoscience. 2016 Nov 15;3(11-12):297-298. doi: 10.18632/oncoscience.324. eCollection 2016. No abstract available.

24.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.

Bone Marrow Transplant. 2017 Mar;52(3):498. doi: 10.1038/bmt.2016.291. Epub 2017 Jan 16. No abstract available.

PMID:
28092355
25.

MARCKS protein overexpression in inflammatory breast cancer.

Manai M, Thomassin-Piana J, Gamoudi A, Finetti P, Lopez M, Eghozzi R, Ayadi S, Lamine OB, Manai M, Rahal K, Charafe-Jauffret E, Jacquemier J, Viens P, Birnbaum D, Boussen H, Chaffanet M, Bertucci F.

Oncotarget. 2017 Jan 24;8(4):6246-6257. doi: 10.18632/oncotarget.14057.

26.

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.

M-Rabet M, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G, Collette Y, Viens P, Gonçalves A, Ginestier C, Charafe-Jauffret E, Birnbaum D, Olive D, Bertucci F, Lopez M.

Ann Oncol. 2017 Apr 1;28(4):769-776. doi: 10.1093/annonc/mdw678.

27.

Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.

Boudin L, Gonçalves A, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Chabannon C.

J Cancer. 2016 Oct 23;7(14):2077-2084. eCollection 2016.

28.

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.

Gonçalves A, Bertucci F, Guille A, Garnier S, Adelaide J, Carbuccia N, Cabaud O, Finetti P, Brunelle S, Piana G, Tomassin-Piana J, Paciencia M, Lambaudie E, Popovici C, Sabatier R, Tarpin C, Provansal M, Extra JM, Eisinger F, Sobol H, Viens P, Lopez M, Ginestier C, Charafe-Jauffret E, Chaffanet M, Birnbaum D.

Oncotarget. 2016 Nov 29;7(48):79428-79441. doi: 10.18632/oncotarget.12714.

29.

Corrigendum to "Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation" [Eur J Cancer 57 (April 2016) 118-126].

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Eur J Cancer. 2016 Nov;67:223. doi: 10.1016/j.ejca.2016.09.002. Epub 2016 Sep 24. No abstract available.

PMID:
27680408
30.

SPAG5: the ultimate marker of proliferation in early breast cancer?

Bertucci F, Viens P, Birnbaum D.

Lancet Oncol. 2016 Jul;17(7):863-865. doi: 10.1016/S1470-2045(16)30092-4. Epub 2016 Jun 14. No abstract available.

PMID:
27312054
31.

Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study.

Decoster C, Gilabert M, Autret A, Turrini O, Oziel-Taieb S, Poizat F, Giovannini M, Viens P, Iovanna J, Raoul JL.

Oncotarget. 2016 Jul 19;7(29):45649-45655. doi: 10.18632/oncotarget.9861.

32.

Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis.

Sabatier R, Sabiani L, Zemmour C, Taix S, Chereau E, Gonçalves A, Jalaguier-Coudray A, Charafe-Jauffret E, Resbeut M, Extra JM, Viens P, Tallet A.

Breast. 2016 Jun;27:8-14. doi: 10.1016/j.breast.2015.12.003. Epub 2016 Mar 19.

PMID:
27212694
33.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.

Bone Marrow Transplant. 2016 Aug;51(8):1082-6. doi: 10.1038/bmt.2016.82. Epub 2016 Apr 4. Erratum in: Bone Marrow Transplant. 2017 Mar;52(3):498.

PMID:
27042835
34.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonneterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY.

Lancet Oncol. 2016 May;17(5):600-11. doi: 10.1016/S1470-2045(16)00011-5. Epub 2016 Mar 28.

PMID:
27032301
35.

Comparative genomic analysis of primary tumors and metastases in breast cancer.

Bertucci F, Finetti P, Guille A, Adélaïde J, Garnier S, Carbuccia N, Monneur A, Charafe-Jauffret E, Goncalves A, Viens P, Birnbaum D, Chaffanet M.

Oncotarget. 2016 May 10;7(19):27208-19. doi: 10.18632/oncotarget.8349.

36.

Contribution of FDG PET/CT for the Optimization of the Management of Additional Lesions Detected on Local Staging Breast MRI.

Jalaguier-Coudray A, Delarbre B, Brenot-Rossi I, Houvenaeghel G, Villard-Mahjoub R, Viens P, Thomassin-Naggara I.

AJR Am J Roentgenol. 2016 Apr;206(4):891-900. doi: 10.2214/AJR.15.14656.

PMID:
27003055
37.

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A.

Oncotarget. 2016 Apr 5;7(14):18531-40. doi: 10.18632/oncotarget.7612.

38.

Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Eur J Cancer. 2016 Apr;57:118-26. doi: 10.1016/j.ejca.2016.01.005. Epub 2016 Feb 23. Erratum in: Eur J Cancer. 2016 Nov;67:223.

PMID:
26918737
39.

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.

Sabatier R, Lavit E, Moretta J, Lambaudie E, Noguchi T, Eisinger F, Cherau E, Provansal M, Livon D, Rabayrol L, Popovici C, Charaffe-Jauffret E, Sobol H, Viens P.

Fam Cancer. 2016 Oct;15(4):497-506. doi: 10.1007/s10689-016-9873-9.

PMID:
26833043
40.

METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors.

Launay S, Sabatier R, Brunelle S, Esterni B, Tarpin C, Viret F, Gravis G, Cappiello M, Provansal M, Extra JM, Bertucci F, Viens P, Goncalves A.

Anticancer Res. 2016 Jan;36(1):293-9.

PMID:
26722056
41.

A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study.

Selle F, Pautier P, Lhommé C, Viens P, Fabbro M, Lokiec F, Gligorov J, Richard S, Provent S, Soares DG, Lotz JP.

Chemotherapy. 2016;61(1):15-22. doi: 10.1159/000440606. Epub 2015 Nov 4.

42.

Chitosanases from Family 46 of Glycoside Hydrolases: From Proteins to Phenotypes.

Viens P, Lacombe-Harvey MÈ, Brzezinski R.

Mar Drugs. 2015 Oct 28;13(11):6566-87. doi: 10.3390/md13116566. Review.

43.

Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.

Rahal S, Boher JM, Extra JM, Tarpin C, Charafe-Jauffret E, Lambaudie E, Sabatier R, Thomassin-Piana J, Tallet A, Resbeut M, Houvenaeghel G, Laborde L, Bertucci F, Viens P, Gonçalves A.

BMC Cancer. 2015 Oct 14;15:697. doi: 10.1186/s12885-015-1746-3.

44.

Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer.

Lhoumeau AC, Martinez S, Boher JM, Monges G, Castellano R, Goubard A, Doremus M, Poizat F, Lelong B, de Chaisemartin C, Bardin F, Viens P, Raoul JL, Prebet T, Aurrand-Lions M, Borg JP, Gonçalves A.

PLoS One. 2015 May 11;10(5):e0123768. doi: 10.1371/journal.pone.0123768. eCollection 2015.

45.

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

Gonçalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, Fabbro M, Lerebours F, Lotz JP, Linassier C, Dohollou N, Eymard JC, Leduc B, Lemonnier J, Martin AL, Boher JM, Viens P, Roché H.

Ann Oncol. 2015 Aug;26(8):1692-7. doi: 10.1093/annonc/mdv216. Epub 2015 May 5.

46.

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.

Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S.

Oncotarget. 2015 May 30;6(15):13506-19.

47.

Uptake of chitosan-derived D-glucosamine oligosaccharides in Streptomyces coelicolor A3(2).

Viens P, Dubeau MP, Kimura A, Desaki Y, Shinya T, Shibuya N, Saito A, Brzezinski R.

FEMS Microbiol Lett. 2015 May;362(9). pii: fnv048. doi: 10.1093/femsle/fnv048. Epub 2015 Apr 2.

PMID:
25837815
48.

Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.

Sabatier R, Calderon B Jr, Lambaudie E, Chereau E, Provansal M, Cappiello MA, Viens P, Rousseau F.

Int J Gynecol Cancer. 2015 Jun;25(5):815-22. doi: 10.1097/IGC.0000000000000418.

PMID:
25768081
49.

Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma.

Duconseil P, Gilabert M, Gayet O, Loncle C, Moutardier V, Turrini O, Calvo E, Ewald J, Giovannini M, Gasmi M, Bories E, Barthet M, Ouaissi M, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Viens P, Iovanna J, Dusetti N.

Am J Pathol. 2015 Apr;185(4):1022-32. doi: 10.1016/j.ajpath.2014.11.029. Epub 2015 Mar 9.

50.

Prognostic and predictive value of PDL1 expression in breast cancer.

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F.

Oncotarget. 2015 Mar 10;6(7):5449-64.

Supplemental Content

Support Center